NYLIM
IBRX icon

New York Life Investment Management’s ImmunityBio IBRX Stock Holding History

New York Life Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-191,221
Closed -$960K – 1424
2023
Q4 		$960K Sell
191,221
-4,408
-2% -$13.8K 0.01% 666
2023
Q3 		$331K Sell
195,629
-30,818
-14% -$61.9K ﹤0.01% 1060
2023
Q2 		$630K Sell
226,447
-36,007
-14% -$102K 0.01% 637
2023
Q1 		$478K Buy
+262,454
New +$816K 0.01% 950

Other funds holding IBRX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

New York Life Investment Management's IBRX Position: Q1 2024 in Review

New York Life Investment Management sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 191,221 shares — an estimated $960K sold.

New York Life Investment Management first reported a position in IBRX in Q1 2023 and held it in 4 quarters. The position peaked at $960K in Q4 2023. 166 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

  • New York Life Investment Management reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
  • New York Life Investment Management sold 191,221 ImmunityBio shares in Q1 2024, an estimated $960K.
  • New York Life Investment Management first reported a position in ImmunityBio in Q1 2023 and held it in 4 quarters.
  • New York Life Investment Management's ImmunityBio position peaked at $960K in Q4 2023.
  • 166 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.